[Interferon therapy in liver cirrhosis]

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic liver disease management remains a challenge.
• Interferon-based therapies have been explored for liver conditions.
• Understanding treatment responses in liver cirrhosis is crucial.

Purpose of the Study:

• To evaluate the efficacy of recombinant interferon alpha 2b in patients with Child A liver cirrhosis.
• To compare different dosage regimens of r-interferon alpha 2b.
• To assess treatment response based on alanine-aminotransferase (ALT) levels.

Main Methods:

• A cohort of patients with liver cirrhosis received r-interferon alpha 2b at two different doses: 9MU/week (n=10) and 3MU/week (n=6).
• Treatment duration was 4 months.
• Response was categorized into Type I (ALT normalization), Type II (50% ALT reduction), and Type III (no response).

Main Results:

• The 9MU/week group showed a 40% Type I response and 40% Type II response.
• The 3MU/week group exhibited a 16.7% Type II response and 83.3% Type III response.
• Higher doses of r-interferon alpha 2b yielded comparable response rates to those seen in chronic active hepatitis treatment.

Conclusions:

• Recombinant interferon alpha 2b demonstrates a dose-dependent therapeutic effect in Child A liver cirrhosis.
• The 9MU/week regimen is more effective than the 3MU/week regimen.
• These findings suggest r-interferon alpha 2b can be a viable treatment option for liver cirrhosis at appropriate doses.